Table III.

Group Mean Percent Change Mucosal Phase II Enzyme Expression^* Compared to Baseline with Oral BSH

BSH Dose	GSTM1	GSTP1	HO-1	NQO1
25 g	−5.60 ± 6.29	1.53 ± 7.89	4.43 ± 7.18	−2.17 ± 4.97
100 g	5.78 ± 12.21	14.10 ± 15.07	15.32 ± 17.95	13.86 ± 19.43
125 g	30.53 ± 48.80	37.47 ± 27.97	37.80 ± 34.21	53.32 ± 41.86
150 g	74.31 ± 69.83	82.83 ± 24.81	105.06 ± 33.49	142.19 ± 86.30
175 g	89.24 ± 63.88	86.19 ± 28.30	106.56 ± 27.28	160.19 ± 65.67
200 g	118.81 ± 39.68	100.80 ± 27.33	120.86 ± 42.66	198.81 ± 48.36
Placebo (Alfalfa 200 g)	28.71 ± 34.01	11.00 ± 48.43	1.14 ± 18.40	1.69 ± 41.21
p-value for BSH 200 g vs. Placebo comparison (Wilcoxon Rank sum test)	0.002	0.004	0.001	0.001
p-value for Slope of BSH Dose-Response linear	<0.001	<0.001	<0.001	0.001

^*Gene mRNA expression ± standard deviation relative to pre-treatment baseline, results for GSTM1 for GSTM1+ subjects only.